Clinical trials Below are current clinical trials.121 studies in Gastroenterology and Hepatology (open studies only). Filter this list of studies by location, status and more. A Study to Detect Pancreatic Cancer Using Circulating Tumor Markers Rochester, Minn. The primary purpose of this study is to select and validate candidate methylated DNA markers (MDMs) (individually and in combined panels) for the detection of pancreative ductal adenocarcinoma (PDAC). The potential complementary value of mutant KRAS and CA19-9 will also be evaluated. A Study to Measure Blood Vessel Health in Non-Pregnant Women Rochester, Minn. This study will allow us to determine normal values for the health of this gel-like layer in non-pregnant women. We will also determine whether values vary from day to day, in the same person. Normal responses from this study will be compared with data obtained in other studies (for example, studies of women who had the pregnancy complication preeclampsia, or women who have other risk factors for heart disease). This will help us to determine whether the glycocalyx contributes to the risk of preeclampsia and heart disease in women with different risk factors. A Study to Compare of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma Rochester, Minn. The purpose of this study is to compare the use of the Glycotest HCC Panel vs. the serum protein biomarker alpha-fetoprotein (AFP) for the early detection of Hepatocellular Carcinoma (HCC). SULF1 and SULF2 Role in Cholangiocarcinoma Rochester, Minn. Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression. A Study to Detect Actionable or Predictive Tumor DNA Mutations in Peripheral Blood (Liquid Biopsy) from Patients with Cholangiocarcinoma (CCA) Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to investigate the feasibility of isolating circulating tumor cells (CTCs) and cfDNA from patients with CCA for molecular characterization and compare the mutation results between peripheral blood and tumor tissue. A Study to Evaluate the Response of Dietary Therapy in Eosinophilic Esophagitis (EoE) Rochester, Minn. The purpose of this study is to investigate the response rate of dietary therapy in patients with Eosinophilic Esophagitis (EoE) and determine rates of long-term compliance with the food elimination diets (SFED, FFED, step-up), and also to identify patient, clinical, and endoscopic factors that may be associated with increased rates of success in patients undergoing dietary therapy in EoE. A Study to Evaluate the Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia Rochester, Minn. The purpose of this study is to understand why patients with indigestion, with or without diabetes, have gastrointestinal symptoms and, in particular, to understand where the symptoms are related to increased sensitivity to nutrients.Subsequently, look at the effects of Ondansetron on these patients' symptoms. A Study to Establish an Obesity-Related Phenotype Registry Rochester, Minn. The purpose of this study is to create a registry of obese patients who have been phenotyped to understand the heterogeneity of obesity. A Study to Develop and Validate Hybrid Molecular Imaging to Transform the Care of Hepatocellular Carcinoma Patients Rochester, Minn. The primary purpose of this study is to evaluate diagnostic performance of 68Ga-PSMA-dual contrast (gadavist and gadoxetate) PET/MRI OR PET/CT for HCC using surgical histopathology (either resection, transplant or biopsy specimens) or LI-RADS® categorization as gold standard. Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Rochester, Minn. This is a single-arm, two-stage, phase II trial to assess the efficacy of futibatinib plus pembrolizumab in advanced hepatocellular carcinoma for patients with FGF19 expression. Patients will receive futibatinib 20mg daily Days 1-21 and will receive pembrolizumab 200mg Day 1 of each 21 day cycle per current clinical standard of care. Patient will receive treatment until disease progression or unacceptable toxicities. Patients will undergo restaging scans every 3 cycles. Subjects will be monitored for adverse events from the beginning of the study drug to 28 days after the last dose. We will collect blood samples for determination of cell free DNA and circulating tumor cells at baseline, after 3 and 6 cycles, and at progression. We will collect tumor biopsy specimens before treatment initiation to develop patient derived tumor organoid. Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page Request an appointment Locations, travel & lodgingResearch July 13, 2023 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, has been recognized as the best Gastroenterology & GI Surgery hospital in the nation for 2023-2024 by U.S. News & World Report. Learn more about this top honor Gastroenterology and HepatologyDepartmenthomeSectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20308333 Medical Departments & Centers Gastroenterology and Hepatology